Our Pipeline

At Apellis, we aim to transform treatment across a broad range of debilitating diseases driven by complement.

We brought forward the first new class of complement medicine in 15 years with the approval of the first targeted C3 therapy. Now, we are advancing that science in multiple clinical and pre-clinical programs across many serious diseases.

Ophthalmology

Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
SYFOVRE®
(pegcetacoplan injection)
GA Approved Marketed in the US
APL-3007 + SYFOVRE
GA Phase I Plan to initiate Ph2 in Q2 2025

RARE DISEASE

Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
EMPAVELI®
(pegcetacoplan)*
PNH Approved Marketed in the US
C3G & IC-MPGN Phase III PDUFA date: July 28, 2025
HSCT-TMA Phase II
FSGS Phase II Plan to initiate pivotal study in H2 2025
DGF Phase II Plan to initiate pivotal study in H2 2025

Neurology

Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
RNA therapies
Undisclosed Preclinical

MULTIPLE THERAPEUTIC AREAS

Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
Gene-edited FcRn therapy (Beam)
Undisclosed Preclinical
Gene-edited complement therapies (Beam)
Undisclosed Preclinical
Oral complement inhibitor
Undisclosed Preclinical

*Sobi has global co-development and ex-U.S. commercialization rights for systemic pegcetacoplan **Initial IND for siRNA
Potential to be registrational

The safety and efficacy of the agents for the indications under investigation have not been established.